• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Theraptc (NQ: ESPR )

    1.680 -0.070 (-4.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,369,430
    Open 1.730
    Bid (Size) 1.680 (2)
    Ask (Size) 1.710 (1)
    Prev. Close 1.750
    Today's Range 1.675 - 1.740
    52wk Range 0.7000 - 3.400
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -42.47%
    -42.47%
    1 Month
    -4.55%
    -4.55%
    3 Month
    -23.98%
    -23.98%
    6 Month
    -26.64%
    -26.64%
    1 Year
    +54.13%
    +54.13%

    More News

    Read More
    Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Report Second Quarter 2024 Financial Results on August 12
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Participate in Upcoming BTIG Biotech Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
    Via Talk Markets
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Via InvestorPlace
    3 Penny Stocks to Buy if You Want to Spend Less and Earn More
    Via InvestorPlace
    Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Esperion to Participate in Upcoming June Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
    Via Benzinga
    Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
    Via AB Newswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.